News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
266,381 Results
Type
Article (14182)
Company Profile (282)
Press Release (251917)
Section
Business (79495)
Career Advice (153)
Deals (13224)
Drug Delivery (35)
Drug Development (50437)
Employer Resources (31)
FDA (5712)
Job Trends (5127)
News (144370)
Policy (10028)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioMidwest Digital (4)
2024 Bio NC Digital (4)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (11)
2024 Biotech Beach Digital (5)
2024 Biotech Beach Standard (3)
2024 Genetown Digital (7)
2024 Genetown Standard (7)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (4)
2025 BioForest Digital (3)
2025 Lone Star Bio Digital (3)
2026 BioMidwest Elite (1)
2026 Biotech Bay Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
Academia (910)
Accelerated approval (2)
Adcomms (12)
Allergies (49)
Alliances (21632)
ALS (60)
Alzheimer's disease (824)
Antibody-drug conjugate (ADC) (86)
Approvals (5727)
Artificial intelligence (107)
Autoimmune disease (10)
Automation (5)
Bankruptcy (104)
Best Places to Work (4560)
BIOSECURE Act (5)
Biosimilars (39)
Biotechnology (232)
Bladder cancer (43)
Brain cancer (19)
Breast cancer (139)
Cancer (1280)
Cardiovascular disease (100)
Career advice (132)
Career pathing (2)
CAR-T (107)
Cell therapy (304)
Cervical cancer (7)
Clinical research (40849)
Collaboration (495)
Compensation (218)
Complete response letters (13)
COVID-19 (1034)
CRISPR (36)
C-suite (141)
Cystic fibrosis (76)
Data (1331)
Denatured (11)
Depression (28)
Diabetes (122)
Diagnostics (1291)
Digital health (3)
Diversity (2)
Diversity, equity & inclusion (9)
Drug discovery (76)
Drug pricing (28)
Drug shortages (3)
Duchenne muscular dystrophy (81)
Earnings (29626)
Editorial (17)
Employer branding (4)
Employer resources (29)
Events (48091)
Executive appointments (396)
FDA (6324)
Featured Employer (32)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (462)
Gene editing (87)
Generative AI (9)
Gene therapy (226)
GLP-1 (353)
Government (1074)
Grass and pollen (2)
Guidances (18)
Healthcare (6586)
Huntington's disease (21)
IgA nephropathy (20)
Immunology and inflammation (78)
Indications (18)
Infectious disease (1096)
Inflammatory bowel disease (110)
Inflation Reduction Act (8)
Influenza (18)
Intellectual property (55)
Interviews (17)
IPO (7261)
IRA (11)
Job creations (860)
Job search strategy (127)
Kidney cancer (6)
Labor market (4)
Layoffs (200)
Leadership (2)
Legal (1386)
Liver cancer (30)
Lung cancer (184)
Lymphoma (81)
Machine learning (1)
Management (7)
Manufacturing (114)
MASH (47)
Medical device (2587)
Medtech (2588)
Mergers & acquisitions (6249)
Metabolic disorders (359)
Multiple sclerosis (51)
NASH (13)
Neurodegenerative disease (57)
Neuropsychiatric disorders (23)
Neuroscience (1187)
NextGen: Class of 2025 (2016)
Non-profit (852)
Northern California (1528)
Now hiring (21)
Obesity (184)
Opinion (100)
Ovarian cancer (59)
Pain (40)
Pancreatic cancer (51)
Parkinson's disease (104)
Partnered (6)
Patents (109)
Patient recruitment (66)
Peanut (35)
People (25485)
Pharmaceutical (48)
Pharmacy benefit managers (5)
Phase I (14421)
Phase II (19006)
Phase III (12013)
Pipeline (678)
Podcasts (46)
Policy (35)
Postmarket research (852)
Preclinical (6059)
Press Release (30)
Prostate cancer (52)
Psychedelics (35)
Radiopharmaceuticals (211)
Rare diseases (270)
Real estate (1414)
Recruiting (12)
Regulatory (8548)
Reports (15)
Research institute (936)
Resumes & cover letters (17)
Rett syndrome (3)
RNA editing (2)
RSV (10)
Schizophrenia (54)
Series A (91)
Series B (59)
Service/supplier (1)
Sickle cell disease (37)
Southern California (1356)
Special edition (11)
Spinal muscular atrophy (117)
Sponsored (11)
Startups (1971)
State (1)
Stomach cancer (4)
Supply chain (18)
The Weekly (33)
United States (11971)
Vaccines (204)
Venture capitalists (28)
Webinars (7)
Weight loss (105)
Women's health (15)
Worklife (2)
Date
Today (10)
Last 7 days (359)
Last 30 days (1518)
Last 365 days (19943)
2025 (4559)
2024 (20552)
2023 (22414)
2022 (26822)
2021 (27805)
2020 (23356)
2019 (16223)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (148)
Alabama (38)
Alaska (2)
Arizona (52)
Arkansas (5)
Asia (17207)
Australia (2915)
California (3479)
Canada (1044)
China (319)
Colorado (135)
Connecticut (143)
Delaware (87)
Europe (37006)
Florida (408)
Georgia (106)
Idaho (16)
Illinois (209)
India (8)
Indiana (85)
Iowa (1)
Japan (68)
Kansas (59)
Kentucky (5)
Louisiana (3)
Maine (11)
Maryland (441)
Massachusetts (2738)
Michigan (69)
Minnesota (134)
Mississippi (1)
Missouri (22)
Montana (14)
Nebraska (4)
Nevada (15)
New Hampshire (14)
New Jersey (871)
New Mexico (12)
New York (949)
North Carolina (516)
North Dakota (4)
Northern California (1528)
Ohio (107)
Oklahoma (9)
Oregon (21)
Pennsylvania (663)
Puerto Rico (3)
Rhode Island (15)
South America (208)
South Carolina (4)
Southern California (1356)
Tennessee (25)
Texas (397)
Utah (48)
Virginia (67)
Washington D.C. (28)
Washington State (316)
Wisconsin (13)
266,381 Results for "acelink therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Rare diseases
AceLink’s Fabry Hopeful Shows Potential in Mid-Stage Study
AceLink is advancing a small-molecule treatment option for Fabry disease that could provide a more convenient alternative to the current enzyme replacement therapy standard.
February 10, 2025
·
2 min read
·
Tristan Manalac
Press Releases
AceLink Therapeutics Presents Interim Results from a Phase 2 Trial of the GCS Inhibitor AL01211 in Treatment-Naïve, Classic Male Fabry Disease Patients at the WORLD Symposium 2025
February 9, 2025
·
3 min read
Drug Development
AceLink Therapeutics Announces Publication of Phase 1 Clinical Trial Data Evaluating AL01211 in Healthy Volunteers
AceLink Therapeutics, Inc. today announced that the findings from their Phase 1 study of AL01211 in healthy volunteers have been published in the peer-reviewed journal Clinical Pharmacology in Drug Development, a journal of the American College of Clinical Pharmacy.
February 26, 2024
·
3 min read
Biotech Bay
AceLink Therapeutics to Present at World Orphan Drug Congress USA
AceLink Therapeutics, Inc. today announced that Jerry Shen, Ph.D., Chief Executive Officer and Co-Founder of AceLink Therapeutics, will present at the World Orphan Drug Congress Conference.
May 17, 2023
·
1 min read
Drug Development
AceLink Announces First Patient Dosed in Phase 2 Trial of AL01211 in Fabry Disease
AceLink Therapeutics, Inc., a clinical-stage biopharmaceutical company developing the next generation of oral substrate reduction therapies (SRTs), announced today that the first patient has been dosed with AL01211 in its Phase 2 trial in China in patients with Fabry disease.
October 31, 2023
·
3 min read
Business
AceLink Therapeutics Appoints Pedro Huertas, M.D., Ph.D., as Chief Medical Officer
AceLink Therapeutics, Inc. today announced the appointment of Pedro Huertas, M.D., Ph.D., as Chief Medical Officer (CMO).
May 8, 2023
·
4 min read
Drug Development
AceLink Therapeutics Receives FDA Clearance to Initiate a Phase 2 Study of AL1211 in Patients with Fabry Disease
AceLink Therapeutics, Inc. today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial of its lead program, AL1211.
June 21, 2023
·
5 min read
Drug Development
AceLink Opens First Clinical Site in China for Phase 2 Study in Fabry Disease
AceLink Therapeutics, Inc. announced the opening of the first clinical trial site in China for its Phase 2, open‑label study of the safety, pharmacokinetics, pharmacodynamics and preliminary measures of physiological efficacy of AL01211 in males with classic Fabry disease who have not been previously treated with other Fabry disease therapies.
August 10, 2023
·
3 min read
Drug Development
AceLink Presents Preclinical Data on AL00804 at WORLD Symposium
AceLink Therapeutics, Inc. (AceLink), an innovative biopharmaceutical company developing transformative therapies for genetic diseases, today presented data on the development of AL00804, a novel brain penetrant glucosylceramide synthase inhibitor, to treat Gaucher disease and other neuronopathic glycosphingolipid (GSL) storage diseases.
February 23, 2023
·
3 min read
Biotech Bay
AceLink Therapeutics to present two posters on Fabry Disease and Gaucher Disease at 2023 WORLD Symposium
AceLink Therapeutics, Inc. announced that the company will present two abstracts featuring the development of AL01211 to treat Fabry disease and AL00804 to treat Gaucher disease and other neuronopathic glycosphingolipid storage diseases at the 19th Annual World Symposium Conference, being held in Orlando, Florida, from February 22-26, 2023.
February 16, 2023
·
2 min read
1 of 26,639
Next